Xeltis Reports Positive 24-Month Clinical Success for Regenerative CABG Conduit

Xeltis, a medtech innovator headquartered in The Netherlands, continues to advance the frontier of regenerative cardiovascular implants with new clinical data supporting its Xabg coronary artery bypass conduit. The company announced encouraging results from a European feasibility study, showing both positive safety and patency outcomes in patients undergoing CABG surgery. This builds upon a prior milestone in which Xabg demonstrated 24-month patency with excellent flow a first for any artificial conduit in human coronary bypass surgery.

Regenerating Coronary Arteries: The Xabg Advantage

At the heart of Xeltis’ technology is its Endogenous Tissue Restoration (ETR) platform, which leverages Nobel Prize-winning polymer science. The approach centers on biorestorative implants scaffolds that guide the body’s natural healing response, allowing new tissue to grow while the scaffold degrades.

Xabg, the company’s small-diameter vascular graft for CABG, is designed to solve a critical pain point: the reliance on painful and risk-prone vein harvesting. Vein grafts remain the standard in 80% of CABG procedures despite their high failure rate. If successful, Xabg could replace autologous grafts with an off-the-shelf alternative, reshaping a market projected to exceed $20 billion by 2035.

Clinical Data: A Regenerative Milestone

Xabg’s promise is underscored by:

EU trial findings showing excellent patency and flow in patients with multi-vessel atherosclerosis.
A 24-month follow-up case where the conduit remained open and functional — the longest durability reported for any artificial bypass graft to date.

Strategic Pipeline and Future Outlook

Xabg marks Xeltis’ second product in clinical development. Its lead candidate, aXess, a restorative vascular access conduit for hemodialysis is already in pivotal trials across the EU and U.S.

Backed by top-tier investors including EQT Life Sciences, Kurma Partners, and DaVita Venture Group, Xeltis is steadily building a diversified platform around regenerative vascular therapies. As patient enrollment in Xabg trials continues, the company edges closer to commercializing a long-awaited solution in the vascular graft space — one built not just for performance, but for healing.

Note: This article contains no forward-looking statements. All outcomes referenced are based on disclosed clinical data as of July 2025.

For more info reference the press release here.

The Business of Biofabrication